Erratum: VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal patients (Modern Pathology (2011) 24 (1404-1412) DOI: 10.1038/modpathol.2011.96);VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal patients

Modern Pathology

Volumn 24, Issue 10, 2011, Pages 1404-1412

  Vlajnic, Tatjana ^a   Andreozzi, Maria Carla ^a   Schneider, Sandra ^a   Tornillo, Luigi ^a   Karamitopoulou, Eva ^b   Lugli, Alessandro ^a   Ruiz, Christian ^a   Zlobec, Inti ^a   Terracciano, Luigi ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

6p12; amplification; colorectal cancer; FISH; prognosis; VEGFA

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; RAS PROTEIN; VASCULOTROPIN A;

ARTICLE; CANCER SURVIVAL; CENTROMERE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 80053563135     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.130     Document Type: Erratum

References (34)

1. Algire GH, Legallais FY. Recent developments in the transparent-chamber technique as adapted to the mouse. J Natl Cancer Inst 1949;10:225-253, incl 8 pl.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
3. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219: 983-985.
4. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-858. (Pubitemid 19162712)
5. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312. (Pubitemid 20066717)
6. Barresi V, Di Gregorio C, Regiani-Bonetti L, et al. Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome. Virchows Arch 2010;457:11-19.
7. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027. (Pubitemid 46202320)
8. Eppenberger M, Zlobec I, Baumhoer D, et al. Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer. BMC Cancer 2010;10:93.
9. Hanrahan V, Currie MJ, Gunningham SP, et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003;200:183-194. (Pubitemid 36748027)
10. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
11. Nakayama Y, Sako T, Shibao K, et al. Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res 2002;22:2437-2442. (Pubitemid 34857079)
12. Yamamori M, Sakaeda T, Nakamura T, et al. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun 2004;325:144-150. (Pubitemid 39441172)
13. Giralt J, Navalpotro B, Hermosilla E, et al. Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy. Oncology 2006;71: 312-319.
14. Zlobec I, Steele R, Nigam N, et al. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. Clin Cancer Res 2005;11:5440-5443. (Pubitemid 41060819)
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
16. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 2009;15:7471-7478.
17. Wagner AD, Arnold D, Grothey AA, et al. Antiangiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev 2009; (3): CD005392.
18. Dallas NA, Fan F, Gray MJ, et al. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev 2007;26:433-441. (Pubitemid 350115100)
19. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24:217-227. (Pubitemid 46622051)
20. Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009;28 (Suppl 1):S32-S37.
21. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009;101: 1308-1324.
22. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005;6: 322-327. (Pubitemid 40590269)
23. Sauter G, Moch H, Carroll P, et al. Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. Int J Cancer 1995;64:99-103.
24. Knuutila S, Bjorkqvist AM, Autio K, et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998;152:1107-1123. (Pubitemid 28221862)
25. Horlings HM, Lai C, Nuyten DS, et al. Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. Clin Cancer Res 2010;16:651-663.
26. Yaginuma Y, Unotoro J, Kamiyama H, et al. Genomic copy-number aberrations related to lymph-node metastasis of colon cancer. J Int Med Res 2006;34: 390-396. (Pubitemid 44363574)
27. Jain L, Vargo CA, Danesi R, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009;8:2496-2508.
28. Odabaei G, Chatterjee D, Jazirehi AR, et al. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 2004;91:169-200. (Pubitemid 39140959)
29. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-499.
30. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008;10:13-27. (Pubitemid 351184831)
31. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010;138:2088-2100.
32. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979-994. (Pubitemid 30602039)
33. Goethals L, Perneel C, Debucquoy A, et al. A new approach to the validation of tissue microarrays. J Pathol 2006;208:607-614.
34. Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol 2008;21 (Suppl 2):S23-S30. (Pubitemid 351592774)